Clinical trials: sponsored by Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
This non-interventional study will include a representative sample of patients with locally advanced or metastatic NSCLC harboring Epidermal Growth Factor Receptor (EGFR)-mutations in Greece.
- Trial name
- NCT02440854
- Testing
- afatinib
- Where
- 7 sites in Greece
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Metastatic Colorectal Cancer (CRC)
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
This study is open to adults with advanced bowel cancer (colorectal cancer) with a KRAS mutation. This is a study in people for whom previous treatment was not successful and surgery is not a treatment option.
- Trial name
- NCT04627142
- Testing
- BI 1701963, Camptosar®
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
COVID-19
ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19
This study is open to adults with COVID-19 infection who are in hospital and receive oxygen. Participants need to be 50 years of age or older and need to be at risk of further worsening of their condition.
- Trial name
- NCT04604184
- Testing
- BI 764198
- Where
- 25 sites in United States, Brazil and 4 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim
Healthy
This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men
The primary objective of this trial is to investigate the safety and tolerability of BI 1265162 in healthy male subjects following inhalative administration of single rising doses.
- Trial name
- NCT03349723
- Testing
- BI 1265162
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)
Non-interventional, Single-country study based on existing data from medical records of COPD patients treated with LAMA or fixed dose combination of ICS/LABA
- Trial name
- NCT04172701
- Testing
- Long-acting Muscarinic Antagonists (LAMA), Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)
- Where
- South Korea
- Volunteers
- 9,284 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Japanese Pradaxa PMS, Long Term
The study objective is to confirm appropriate use and safety profile of Prazaxa® Capsules in real-world setting after the availability of idarucizumab
- Trial name
- NCT03175198
- Testing
- Prazaxa® Capsules
- Where
- Japan
- Volunteers
- 5,660 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease
To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting
- Trial name
- NCT02864407
- Testing
- Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
- Where
- South Korea
- Volunteers
- 3,223 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III…
- Trial name
- NCT01619085
- Testing
- Nintedanib
- Where
- 173 sites in United States, Australia and 22 more
- Volunteers
- 752 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)
A retrospective analysis study in COPD patients for an exact follow-up period of 12 months (in subgroup analyses: 24 and 36 months); censoring of patients will only be done in case a patient died during the respective follow-up…
- Trial name
- NCT04097223
- Where
- Germany
- Volunteers
- 17,464 people
- Sponsor
- Boehringer Ingelheim
Multiple Myeloma
Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients
The primary objective of this trial is to determine the maximum tolerated dose (MTD) of BI 836909 administered by continuous i.v. infusion in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT02514239
- Testing
- BI 836909
- Where
- 5 sites in France, Germany
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim
Healthy
This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.
The primary objective of this trial is to investigate the safety and tolerability of BI 1265162 in healthy male subjects following inhalative administration of multiple rising doses.
- Trial name
- NCT03576144
- Testing
- BI 1265162
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
The objectives of this study are to assess the risk of ketoacidosis, severe urinary tract infections, volume depletion, and dehydration associated in patients with T2DM initiating Empagliflozin compared to patient initiating a…
- Trial name
- NCT03764631
- Testing
- Empagliflozin, Dipeptidyl-peptidase 4 (DPP-4) inhibitors
- Where
- 21 sites in Saudi Arabia
- Volunteers
- 1,502 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of long-term daily use of JARDIANCE® Tablets in Japanese patients with type 2 diabetes mellitus
- Trial name
- NCT02489942
- Testing
- Jardiance
- Where
- Japan
- Volunteers
- 8,145 people
- Sponsor
- Boehringer Ingelheim
Squamous Non-small Cell Lung Cancer
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second…
- Trial name
- NCT04552535
- Testing
- Second line (2L) afatinib, Second line chemotherapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Effect of BIBW 2948 BS in COPD
Study of BIBW 2948 BS in Patients with COPD and Chronic Bronchitis
- Trial name
- NCT00423137
- Testing
- BIBW 2948 BS
- Where
- 6 sites in United States, Germany
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal and sub-optimal Peak Inspiratory Flow…
- Trial name
- NCT04223843
- Testing
- Tiotropium + olodaterol
- Where
- 26 sites in United States, Germany
- Volunteers
- 213 people
- Sponsor
- Boehringer Ingelheim
Hemorrhage
Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients
Idarucizumab is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran with very high affinity. Idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises its anticoagulant…
- Trial name
- NCT02798107
- Testing
- idarucizumab
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
To assess the comparative effectiveness of combination Tiotropium and Olodaterol (Tio+Olo) (FDC) compared to combination LAMA/LABA and ICS (fixed or open), and to explore whether this varies across COPD sub populations defined by…
- Trial name
- NCT04184297
- Testing
- Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
- Where
- United States
- Volunteers
- 27,190 people
- Sponsor
- Boehringer Ingelheim
COPD
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS
The primary objective is to compare the effectiveness of maintenance therapy initiation with the combination treatment Tiotropium and Olodaterol (Olo+Tio) compared with LABA/ICS combination in COPD as the time to the first COPD…
- Trial name
- NCT04138758
- Testing
- Tiotropium bromide + Olodaterol, LABA/ICS
- Where
- United States
- Volunteers
- 42,953 people
- Sponsor
- Boehringer Ingelheim
Lupus Erythematosus, Systemic
BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)
The main objective of this study is to assess the safety, tolerability and pharmacokinetics of orally administered BI 705564 in patients with systemic lupus erythematosus
- Trial name
- NCT03771885
- Testing
- BI 705564
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.